Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
J Toxicol Sci ; 41(1): 91-104, 2016 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-26763396

RESUMO

We previously reported that 28-day exposure to hepatocarcinogens that facilitate cell proliferation specifically alters the expression of G1/S checkpoint-related genes and proteins, induces aberrant early expression of ubiquitin D (UBD) at the G2 phase, and increases apoptosis in the rat liver, indicating G1/S and spindle checkpoint dysfunction. The present study aimed to determine the time of onset of carcinogen-specific cell-cycle disruption after repeated administration of renal carcinogens for up to 28 days. Rats were orally administered the renal carcinogens nitrofurantoin (NFT), 1-amino-2,4-dibromoantraquinone (ADAQ), and 1,2,3-trichloropropane (TCP) or the non-carcinogenic renal toxicants 1-chloro-2-propanol, triamterene, and carboxin for 3, 7 or 28 days. Both immunohistochemical single-molecule analysis and real-time RT-PCR analysis revealed that carcinogen-specific expression changes were not observed after 28 days of administration. However, the renal carcinogens ADAQ and TCP specifically reduced the number of cells expressing phosphorylated-histone H3 at Ser10 in both UBD(+) cells and proliferating cells, suggestive of insufficient UBD expression at the M phase and early transition of proliferating cells from the M phase, without increasing apoptosis, after 28 days of administration. In contrast, NFT, which has marginal carcinogenic potential, did not induce such cellular responses. These results suggest that it may take 28 days to induce spindle checkpoint dysfunction by renal carcinogens; however, induction of apoptosis may not be essential. Thus, induction of spindle checkpoint dysfunction may be dependent on carcinogenic potential of carcinogen examined, and marginal carcinogens may not exert sufficient responses even after 28 days of administration.


Assuntos
Antraquinonas/administração & dosagem , Antraquinonas/toxicidade , Rim/citologia , Pontos de Checagem da Fase M do Ciclo Celular/efeitos dos fármacos , Nitrofurantoína/administração & dosagem , Nitrofurantoína/toxicidade , Propano/análogos & derivados , Animais , Peso Corporal/efeitos dos fármacos , Carboxina/administração & dosagem , Carboxina/toxicidade , Proliferação de Células/efeitos dos fármacos , Cloridrinas/administração & dosagem , Cloridrinas/toxicidade , Histonas/metabolismo , Rim/efeitos dos fármacos , Masculino , Tamanho do Órgão/efeitos dos fármacos , Propano/administração & dosagem , Propano/toxicidade , Ratos Endogâmicos F344 , Fatores de Tempo , Triantereno/administração & dosagem , Triantereno/toxicidade , Ubiquitinas/metabolismo
3.
Int J Toxicol ; 20(6): 363-8, 2001.
Artigo em Inglês | MEDLINE | ID: mdl-11797818

RESUMO

The in vitro antioxidant and photo-oxidant activity of dipyridamole was studied by its effect on superoxide- and singlet oxygen-mediated photohemolysis and viability of neutrophils. Dipyridamole was found to be phototoxic when examined by the photohemolysis on human erythrocytes and on linoleic acid as lipid peroxidation model at concentrations above 3.0 x 10(-5) M. On the contrary, when lower concentrations (1.0 x 10(-5) to 1.0 x 10(-6) M) were used, dipyridamole showed a protector action against singlet oxygen-mediated photohemolysis by other phototoxic compounds like triamterene. This antioxidant property is proposed to result from quenching of triamterene mediated by fluorescence energy transfer. Auto-oxidation and fluorescence-energy transfer is clearly an important mechanism for protection for this drug.


Assuntos
Antioxidantes/farmacologia , Dipiridamol/farmacologia , Dipiridamol/toxicidade , Hemólise/efeitos dos fármacos , Fotólise , Inibidores da Agregação Plaquetária/farmacologia , Inibidores da Agregação Plaquetária/toxicidade , Sequestradores de Radicais Livres/farmacologia , Hemólise/efeitos da radiação , Humanos , Técnicas In Vitro , Cinética , Ácido Linoleico , Oxigênio Singlete , Espectrofotometria Ultravioleta , Superóxidos , Triantereno/toxicidade , Raios Ultravioleta
5.
Pharmazie ; 50(6): 419-21, 1995 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-7651980

RESUMO

Acidic and basic triamterene derivatives were evaluated with respect to their acute toxicity. After single intravenous application in mice, derivatives with a basic side-chain were much more toxic than compounds with an acidic side-chain. There is a significant correlation between the potassium retaining properties (measured as ED50) and the acute toxicity (measured as LD50) of the substances. The low acute toxicity after oral application of the compounds can be explained by their low oral bioavailability.


Assuntos
Triantereno/análogos & derivados , Triantereno/toxicidade , Animais , Disponibilidade Biológica , Concentração de Íons de Hidrogênio , Injeções Intravenosas , Dose Letal Mediana , Masculino , Camundongos , Relação Estrutura-Atividade , Triantereno/administração & dosagem
6.
Drug Des Deliv ; 1(2): 143-50, 1986 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-3509327

RESUMO

Mechanistic biochemistry (consideration of metabolism in the context of knowledge of contemporary biochemistry) was applied to propanolol (1), hydrochlorothiazide (2), hydralazine (3), and triamterene (4), representative of the main types of anti-hypertensive drugs in common use. Three routes of metabolism, that is, acetylation, generation of free radicals (leading to peroxidation of lipids), and osazone formation were considered in relation to the structures of these drugs. The possibility that acetylation can lead to hepatic toxicity, lipid peroxidation to membrane lesion, and osazone formation to glucose and energy depletion was highlighted. Hydralazine, with its potential for osazone formation and great susceptibility to acetylation and free radical formation, was judged most capable of giving rise to these side effects, in agreement with reported toxicity. Triamterene was judged less susceptible than hydralazine to acetylation and free radical formation, and hydrochlorothiazide even less so. Propanolol is immune to any of these consequences.


Assuntos
Anti-Hipertensivos/metabolismo , Acetilação , Anti-Hipertensivos/toxicidade , Biotransformação , Radicais Livres , Glucose/metabolismo , Hidralazina/metabolismo , Hidralazina/toxicidade , Hidroclorotiazida/metabolismo , Hidroclorotiazida/toxicidade , Peroxidação de Lipídeos/efeitos dos fármacos , Propranolol/metabolismo , Propranolol/toxicidade , Triantereno/metabolismo , Triantereno/toxicidade
7.
Fundam Appl Toxicol ; 7(4): 533-46, 1986 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-3803749

RESUMO

Triamterene (2,4,7-triamino-6-phenylpteridine), a widely used diuretic/antihypertensive agent with weak antifolate activity, has been found to be positive in several in vitro assays for mutagenicity. The present studies were undertaken to characterize the potential mutagenic and antifolate activity of triamterene in the bone marrow and testes of mice with in vivo treatment. Triamterene had no clastogenic effects on the bone marrow at 6, 16, or 24 hr after a single oral dose of 25, 125, or 250 mg/kg. No alterations in hematopoietic cell maturation characteristic of antifolate action were observed in a dose-range study in which triamterene was orally administered to mice at 5-300 mg/kg/day for 5 days. Triamterene had no adverse effects on mating or fertility and did not induce dominant lethal mutations in the germ cells of male mice when given for 5 days at 5-100 mg/kg/day. Oral exposure to mice under identical conditions had no effect on testicular weight, DNA content, or activity of the de novo pathway for thymidine synthesis from deoxy [6-3H]uridine. The present findings are consistent with an absence of mutagenic effect and antifolate action on the bone marrow and testes with in vivo administration.


Assuntos
Mutagênicos , Mutação , Testículo/patologia , Triantereno/toxicidade , Animais , Medula Óssea/efeitos dos fármacos , Medula Óssea/patologia , Ciclofosfamida/toxicidade , Replicação do DNA/efeitos dos fármacos , Genes Dominantes , Genes Letais , Masculino , Metáfase , Camundongos , Testículo/efeitos dos fármacos , Timidina/biossíntese
8.
J Pharm Sci ; 75(2): 129-32, 1986 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-3958920

RESUMO

In an attempt to explain the triamterene stone diathesis, we studied the excretion and solubility of triamterene, 1, and its metabolite, the sulfate ester of the hydroxy derivative of triamterene, 3. The urinary excretion pattern and metabolism in stone formers was the same as in other chronic users of triamterene or healthy volunteers. The solubility of triamterene in urine was approximately one-half of its solubility in buffer solution, whereas the sulfate ester, 3, was nearly twice as soluble in urine as in the buffer solution. In the majority of the subjects studied, we found concentrations of 3 which approached or exceeded apparent solubility limits in urine. This was not true for triamterene where most measured urine concentrations were less than the apparent solubility as determined by equilibration. Alteration in the metabolism of triamterene is probably not a causative factor for triamterene nephrolithiasis. The saturation of urine with triamterene and especially with the sulfate ester, 3, may be related to stone formation, but other physical factors play a role in determining the relative amounts of drug found in calculus material.


Assuntos
Nefrocalcinose/induzido quimicamente , Triantereno/metabolismo , Adulto , Soluções Tampão , Cromatografia em Camada Fina , Humanos , Hidroclorotiazida/farmacologia , Concentração de Íons de Hidrogênio , Masculino , Nefrocalcinose/metabolismo , Solubilidade , Triantereno/toxicidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA